Applied Therapeutics Inc.
06/12/2025 | Press release | Distributed by Public on 06/12/2025 04:01
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2025 Annual Meeting of Stockholders (the "Annual Meeting") held on June 9, 2025, the stockholders of Applied Therapeutics, Inc. (the "Company") voted on the matters described below.
1.
The Company's stockholders elected one Class III director, who is the only director of such class, to serve until the 2028 Annual Meeting of Stockholders and until her successor is duly elected and qualified or until her earlier death, resignation or removal. The numbers of shares that voted for the election of such director, abstained from voting for such director and represented broker non-votes with respect to this proposal are summarized in the table below.
|
Director Nominee |
Votes For |
Abstentions |
Broker Non-Votes |
|||
|
Teena Lerner, Ph.D. |
44,287,976 |
17,031,078 |
39,277,498 |
2.
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The numbers of shares that voted for, against and abstained from voting for or against the ratification of the appointment of Ernst & Young LLP are summarized in the table below.
|
Votes For |
Votes Against |
Abstentions |
||
|
99,429,280 |
679,553 |
725,233 |
3.
The Company's stockholders voted to approve (on a non-binding advisory basis) the compensation of our named executive officers as described in the accompanying materials. The number of shares that voted for, against, abstained from voting for or against this proposal and represented broker non-votes with respect to this proposal are summarized in the table below.
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
|
57,650,206 |
3,307,662 |
598,700 |
39,277,498 |
4.
The Company's stockholders voted to approve (on a non-binding advisory basis) the frequency of an advisory vote on the compensation of our named executive officers in future years. The number of shares that voted for one year, two years, three year, abstained from voting and represented broker non-votes with respect to this proposal are summarized in the table below.
|
One Year |
Two Years |
Three Years |
Abstentions |
Broker Non-Votes |
||||
|
60,589,660 |
144,599 |
275,839 |
546,470 |
39,277,498 |
After taking into consideration the foregoing voting results and the prior recommendations of the board of directors and the compensation committee thereof, the Company will hold an advisory "say-on-pay" vote every one year in connection with its annual meeting of stockholders until the board of directors otherwise determines that a different frequency for such advisory votes is in the best interest of the Company.
5.
The Company's stockholders voted to approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to combine the outstanding shares of the Company's common stock, par value $0.0001 per share, into a lesser number of outstanding shares, by a ratio of not less than one-for-5 and not more than one-for-40, with the exact ratio to be set within this range by our board of directors in its sole discretion. The number of shares that voted for, against and abstained from voting for or against such amendment are summarized in the table below.
|
Votes For |
Votes Against |
Abstentions |
||
|
92,238,511 |
8,537,480 |
58,075 |
Applied Therapeutics Inc. published this content on June 12, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 12, 2025 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io